TABLE ROCK LABORATORIES, INC. – Trademark Portfolio

Entity Type: 03

TABLE ROCK LABORATORIES, INC. holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. The owner is based in GREENVILLE, SC.

812 HAMPTON AVENUE

GREENVILLE, SC

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CITHAL
CITHAL
Cancelled 1951
CITRIN
CITRIN
Cancelled 1947
YEASTAGA
YEASTAGA
Cancelled 1947
TAVILEN
TAVILEN
Cancelled 1947
TABEROC
TABEROC
Cancelled 1947
ROIDIN
ROIDIN
Cancelled 1947
ESPERON
ESPERON
Cancelled 1947
NIBESOL
NIBESOL
Cancelled 1947
BEFACLIN
BEFACLIN
Cancelled 1947
ZIBORAL
ZIBORAL
Cancelled 1947

Trademark Classifications

TABLE ROCK LABORATORIES, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (12 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does TABLE ROCK LABORATORIES, INC. have?

TABLE ROCK LABORATORIES, INC. has 13 U.S. trademarks filed with the USPTO.

What trademark classes does TABLE ROCK LABORATORIES, INC. file in?

TABLE ROCK LABORATORIES, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is TABLE ROCK LABORATORIES, INC.'s trademark registration success rate?

TABLE ROCK LABORATORIES, INC. has a 0% trademark registration rate, with 0 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.